Search results
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
WTNH-TV New Haven· 6 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study...
Causes and symptoms of the most common cancers in each age group revealed
The US Sun· 5 days agoTHERE are a thousand new cancer cases diagnosed every day in the UK – but some types can be avoided...
Lima Memorial Partners with Eon for AI-Powered Early Cancer Detection Program
Your Hometown Lima Stations· 8 hours agoThis collaboration will help Lima Memorial use the latest Artificial Intelligence (AI) technology to...
Early onset bowel cancer cases increasing in New Zealand
Medical Xpress· 1 day agoThe findings, published in BMC Cancer, show that while colorectal cancer rates (CRC) in older age groups have actually decreased (possibly in part due to ...
Sumitomo Pharma Presents Urology and Oncology Data at AUA 2024 Annual Meeting
WTRF Wheeling· 2 days agoSumitomo Pharma America, Inc., (SMPA) today announced the presentation of data from URO-901-3005, a Phase 3 randomized, double-blind, parallel-group, fixed-dose study evaluating the efficacy ...
Tip Sheet: Funding awarded to two ovarian cancer research projects, progress towards liquid biopsies...
Newswise· 7 days agoSEATTLE — May 3, 2024 — Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. If you’re covering the annual meeting of ...
You might have missed: space cloverleaf; mindfulness & more
Cosmos· 4 days agoIn 2021, astronomers discovered enormous circular radio features around some galaxies. Since then,...
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
WTNH-TV New Haven· 4 days agoA host-directed and potentially broad acting twice-daily oral, small molecule, opaganib is in development for multiple indications, including COVID-19, acute respiratory distress syndrome, oncology ...
Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate Update
WTNH-TV New Haven· 2 days ago"During the first quarter and subsequent period, we have continued to advance both the phase 2 CALLIPER trial in patients with progressive multiple sclerosis (PMS) and the ...